𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Where does the combination of sorafenib and interferon in renal cell carcinoma stand?

✍ Scribed by Keith T. Flaherty

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
73 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Sorafenib can be combined safely with interferon, but the results of a recent randomized, phase 2 trial cast doubt on the value of further evaluating this combination. The renal cell carcinoma field continues to wrestle with the value of combining β€œtargeted” therapies with cytokines.

πŸ“œ SIMILAR VOLUMES

Upfront, randomized, phase 2 trial of so
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma : Clinical and biomarker analysis
✍ Eric Jonasch; Paul Corn; Lance C. Pagliaro; Carla L. Warneke; Marcella M. Johnso πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 149 KB

## Abstract ## BACKGROUND: The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low‐dose interferon‐alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC). ## METHODS: Untreated patients with cle

Sorafenib reduces the percentage of tumo
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
✍ Ingrid M.E. Desar; J. (Hans) F.M. Jacobs; Christina A. Hulsbergen-vandeKaa; Wim πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 335 KB πŸ‘ 2 views

## Abstract Tyrosine kinase inhibitors (TKIs) as sorafenib are known to reduce the number of immunosuppressive regulatory T cells (Tregs) in the peripheral blood and thereby shifting the immune balance to a more stimulating setting. The effect of sorafenib on intratumoural Tregs is unclear but impo

Safety and efficacy results of the advan
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
✍ Walter M. Stadler; Robert A. Figlin; David F. McDermott; Janice P. Dutcher; Jenn πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 222 KB

## Abstract ## BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval. ## METHODS: In this nonrandomized, open‐label expanded access program, 2504 patients from the United St

Recombinant interferon Ξ±-2A combined wit
Recombinant interferon Ξ±-2A combined with prednisone in metastatic renal-cell carcinoma: Treatment results, serum interferon levels and the development of antibodies
✍ Sophie D. FossΓ₯; Gustav Lehne; Ragnhild Gunderson; Unni Hielmaas; Eduard E. Hold πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 French βš– 375 KB πŸ‘ 1 views

Five partial responses were seen in 23 patients with metastatic renal-cell carcinoma (MRCC) receiving interferon-a 2a (IFN) + prednisone (P). Four of 24 subsequent patients responded to IFN + P (combined response rate 19%). The median response duration was 8 months (3 to 30 months). The one-year sur